BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36642703)

  • 1. Advances in Medical Treatment of Primary Aldosteronism.
    Li YJ; Ji ZG; Wen J
    Chin Med Sci J; 2023 Mar; 38(1):49-56. PubMed ID: 36642703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
    Wachtel H; Fraker DL
    Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
    Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
    Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary aldosteronism: Practical recommendations for treatment and follow-up.
    Araujo-Castro M; Pascual-Corrales E; Martín Rojas P; Parra Ramírez P
    Hipertens Riesgo Vasc; 2023; 40(4):215-221. PubMed ID: 37993292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
    Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
    Weiner ID
    Semin Nephrol; 2013 May; 33(3):265-76. PubMed ID: 23953804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of drug-based and surgical treatments for primary aldosteronism.
    Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
    Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys.
    Cohen JB; Bancos I; Brown JM; Sarathy H; Turcu AF; Cohen DL
    Annu Rev Med; 2023 Jan; 74():217-230. PubMed ID: 36375469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
    Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
    Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
    Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
    Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Treatment of Patients With Primary Aldosteronism.
    Obeid H; Chen Cardenas SM; Khairi S; Turcu AF
    Endocr Pract; 2023 Jun; 29(6):484-490. PubMed ID: 36273684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
    Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Aldosteronism: Present and Future.
    Funder JW
    Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.
    Hundemer GL
    Curr Cardiol Rep; 2019 Jul; 21(9):93. PubMed ID: 31352525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary aldosteronism: Clinical practice guidelines of the Taiwan Society of Aldosteronism.
    Tseng CS; Chan CK; Lee HY; Pan CT; Peng KY; Wang SM; Huang KH; Tsai YC; Wu VC; Chueh JS;
    J Formos Med Assoc; 2024 Mar; 123 Suppl 2():S125-S134. PubMed ID: 37328332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.